BioLine Rx (BioLine Rx) Pre-Tax Income : $-60.62 Mil (TTM As of Dec. 2023)

View and export this data going back to 2011. Start your Free Trial

What is BioLine Rx Pre-Tax Income?

Pretax income is the income that a company earns before paying income taxes. BioLine Rx's pretax income for the three months ended in Dec. 2023 was $-13.89 Mil. Its pretax income for the trailing twelve months (TTM) ended in Dec. 2023 was $-60.62 Mil. BioLine Rx's pretax margin was -289.27%.

During the past 13 years, BioLine Rx's highest Pretax Margin was -1262.81%. The lowest was -1262.81%. And the median was -1262.81%.

BioLine Rx Pre-Tax Income Historical Data

The historical data trend for BioLine Rx's Pre-Tax Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioLine Rx Pre-Tax Income Chart

BioLine Rx Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Pre-Tax Income

Get a 7-Day Free Trial

-25.45

-30.02

-27.05

-24.95

-60.62

BioLine Rx Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Pre-Tax Income	Get a 7-Day Free Trial															-5.73	-12.16	-18.55	-16.02	-13.89

Competitive Comparison of BioLine Rx's Pre-Tax Income

For the Biotechnology subindustry, BioLine Rx's Pre-Tax Income, along with its competitors' market caps and Pre-Tax Income data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

BioLine Rx's Pre-Tax Income Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, BioLine Rx's Pre-Tax Income distribution charts can be found below:

* The bar in red indicates where BioLine Rx's Pre-Tax Income falls into.

BioLine Rx Pre-Tax Income Calculation

This is the income that a company earns before paying income taxes.

BioLine Rx's Pretax Income for the fiscal year that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-42.992	+	-17.461	+	-2.144	+	2.007	+	-0.025000000000006
	=	-60.62

BioLine Rx's Pretax Income for the quarter that ended in Dec. 2023 is calculated as

Pretax Income	=	Operating Income	+	Non Operating Income	+	Interest Expense	+	Interest Income	+	Other
	=	-11.864	+	-3.671	+	0.957	+	0.718	+	-0.025
	=	-13.89

Pre-Tax Income for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-60.62 Mil.

BioLine Rx (NAS:BLRX) Pre-Tax Income Explanation

BioLine Rx's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pretax Income	/	Revenue
	=	-13.885	/	4.8
	=	-289.27%

During the past 13 years, BioLine Rx's highest Pretax Margin was -1262.81%. The lowest was -1262.81%. And the median was -1262.81%.

BioLine Rx Pre-Tax Income Related Terms

Thank you for viewing the detailed overview of BioLine Rx's Pre-Tax Income provided by GuruFocus.com. Please click on the following links to see related term pages.

BioLine Rx (BioLine Rx) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » BioLine Rx Ltd (NAS:BLRX) » Definitions » Pre-Tax Income

Comparable Companies

Traded in Other Exchanges

BLRX:Israel YP2A:Germany YP2A:Germany

Address

2 HaMa’ayan Street, Modi’in, ISR, 7177871

Website

https://www.biolinerx.com

BioLine Rx Ltd is a pre-commercial-stage biopharmaceutical company focused on oncology. The company's current development and commercialization pipeline consists of two clinical-stage therapeutic candidates motixafortide (BL-8040), a novel peptide for the treatment of stem-cell mobilization and solid tumors, and AGI-134, an immuno-oncology agent in development for solid tumors. In addition, the company has an off-strategy, legacy therapeutic product called BL-5010 for the treatment of skin lesions. The company has generated revenues from milestone payments under previously existing out-licensing agreements.